Thermo Fisher reports Q3 adj. EPS $2.94, consensus $2.87
Reports Q3 revenue $6.27B, consensus $6.18B. We're pleased to continue our strong momentum in the third quarter, with excellent performance on the top and bottom line," said Marc Casper, president and CEO of Thermo Fisher. "Our team executed very well and captured opportunities to gain share and drive growth. We continued to enhance our value proposition to be an even stronger partner for our customers. Among the highlights, we launched innovative new products across our analytical instrument, bioproduction and genetic sciences businesses. We further strengthened our global capabilities to support growth, opening new facilities in the U.S. and China. We were also pleased to close our acquisition of the GSK site in Ireland, significantly expanding our API manufacturing network to meet customer demand for our pharma services."